How MedAccess’ partnerships are delivering impact
We've published our 2024 Impact Case Studies
The stories go behind the headline impact to look at the public health and market challenges we sought to address and how we helped bring the benefits of medical innovation to more people more quickly.
For example, since 2017, MedAccess-supported products have led to:
🔹 20,300 P. vivax malaria relapses being averted due to G6PD tests enabling better malaria treatment
🔹 39,500 stillbirths being averted thanks to better access to dual HIV/syphilis tests
🔹 482,000 additional people testing for HIV because they had access to a self-test
Watch a new film on the rollout of G6PD testing and tafenoquine in Brazil
In 2024, Brazil became the first country to introduce both G6PD testing and tafenoquine treatment into national P. vivax malaria programmes.
Tafenoquine is a single-dose treatment that eliminates the malaria parasite from the liver, preventing relapse. However, it can cause severe anaemia in patients who are deficient in the enzyme G6PD. The World Health Organization (WHO) recommends health workers conduct a G6PD deficiency test prior to the treatment of P. vivax malaria patients, to guide treatment decisions. We supported access to G6PD testing by providing a volume guarantee to SD Biosensor.
A new film from MedAccess, Medicines for Malaria Venture and PATH tells the story of the rollout in Brazil - and why the test and treatment will contribute towards the country's efforts to eliminate P. vivax malaria.
Welcoming our newest Board member, Dr Angela Gichaga
We’re delighted to welcome Dr Angela Gichaga, a public and social sector leader, to the MedAccess Board.
Dr Gichaga has a wealth of experience in civil service, management consulting, NGOs, and academia. She is the Global President and CEO of the Financing Alliance for Health, which works to develop resilient and sustainably financed primary and community health systems. Dr Gichaga is also the Co-Executive Director of Africa Frontline First, an organisation that deploys innovative financing mechanisms across Africa.
Work with us
Recommended by LinkedIn
We’re looking for a new Head of Institutional Fundraising
The ideal candidate will be a highly networked and experienced fundraiser who can help MedAccess deliver long-term, transformational health impact.
They will play a key role in developing, cultivating, stewarding and retaining a network of donors and prospects to ensure sufficient grant income to help MedAccess increase its impact.
The application deadline is 5 December 2024.
News from our partners
Access to Medicine Foundation launches 2024 Index
The 2024 Access to Medicine Index ranks 20 of the world’s largest pharmaceutical companies on their efforts to improve access to essential medicines in low- and middle-income countries (LMICs).
The Index notes that there has been a growing trend of companies prioritising LMICs in their inclusive business models. However, it also finds that the overall pace of progress has slowed and growing healthcare needs in underserved communities aren’t being met.
What we've been reading
UNAIDS has released its annual report, 'Take the rights path to end AIDS'. The report delves into the importance of upholding human rights if we are to end AIDS as a public health threat by 2030.
This article from the Clinton Health Access Initiative explores progress on increasing vaccine manufacturing across Africa. It provides an update a year on from its 2023 research with the Africa Centres for Disease Control and Prevention (Africa CDC) and PATH on the state of vaccine manufacturing on the continent.
The WHO study identifies 17 priority pathogens for vaccine research and development based on disease burden, antimicrobial resistance and socioeconomic impact. The list aims to guide global vaccine efforts, focusing on equitable access and reducing public health burdens, aligning with the Immunisation Agenda 2030.
Glenda Gray, Board Chair of the Global Antibiotic Research & Development Partnership (GARDP), writes about the need to ensure safe and effective antibiotics are available for paediatric use in LMICs.